Scarlet plans to utilize its new seventy-five million dollars in total capital to expand its specialized team of AI reviewers and engineers into the Asia-Pacific market. This aggressive expansion follows a successful fifty million dollar Series B funding round led by Headline, with significant contributions from Notion Capital, Atomico, and Creandum. The London-based startup, founded by veterans from Babylon Health, aims to resolve the persistent tension between rapid technological progress and the sluggish pace of medical device certification. Currently, a sophisticated diagnostic model can be trained in just a few weeks, yet the administrative path to clinical deployment often stretches over eighteen months. This disparity creates a dangerous lag, preventing patients from accessing life-saving tools while developers wait for bureaucratic clearance. By positioning itself at the intersection of deep tech and regulatory expertise, the company seeks to bridge this divide through specialized review processes that recognize the iterative nature of modern software.
Modernizing the Certification Landscape
The core of the current regulatory crisis lies in the fact that most certifying bodies are generalists, tasked with evaluating everything from hip replacements to MRI hardware. This lack of specialization often leads to prolonged review times and misunderstandings of how software actually functions. Scarlet distinguishes itself by operating as an AI-native regulatory body, holding official designations as an EU notified body, a UK approved body under the MHRA, and a US FDA Third Party Review Organization. Among the fifty-two EU-designated bodies, it stands as the only entity focused exclusively on software and artificial intelligence. This focus allows the organization to employ experts who understand neural networks and algorithmic bias as deeply as they understand clinical safety. By narrowing its scope, the firm ensures that the evaluation process is not just a checkbox exercise but a rigorous, technically informed assessment that matches the sophistication of the tools being reviewed.
Traditional certification cycles typically require twelve to eighteen months for an initial release, with even minor updates potentially adding another half-year to the timeline. For a developer releasing iterative improvements, this legacy system acts as a complete stop to progress, forcing them to choose between stagnation and non-compliance. Building on this foundation, the new model introduces a more fluid framework where certification is treated as an ongoing relationship rather than a static event. This shift is vital because modern medical software is never truly finished; it learns, evolves, and requires frequent security patches or performance tuning. By aligning certification with agile development cycles, the platform allows for a more responsive environment where safety standards are maintained without stifling the creative momentum of engineers. This approach effectively removes the administrative bottleneck that has historically characterized the transition from laboratory prototype to clinical application.
Engineering Safety Through Global Implementation
The transition from a one-off assessment to a subscription-based regulatory model represented a fundamental change in how compliance is handled in the healthcare industry. Instead of submitting massive, static dossiers that quickly become obsolete, developers can now upload technical documentation in their existing formats directly to a centralized platform. This documentation is then evaluated by qualified human reviewers who utilize automated tools to streamline the administrative burden. This integration of technology with human expertise ensures that the focus remains on high-level safety considerations rather than manual data entry or formatting errors. Furthermore, this system supports continuous surveillance, allowing for real-time monitoring of how a product performs once it enters the market. Such transparency is crucial for maintaining public trust in AI, as it provides a verifiable audit trail that covers the entire lifecycle of the device, ensuring that performance remains consistent over time.
The decision to expand into the United States and the Asia-Pacific region reflected a broader commitment to establishing a unified global standard for medical software safety. By scaling the team of AI reviewers, the organization positioned itself to handle the surge in demand expected from 2026 to 2028. It became evident that healthcare stakeholders who prioritized the adoption of these agile regulatory frameworks ensured their internal development processes remained competitive and compliant. It was essential for the industry to move beyond the mindset of regulation as a barrier, instead viewing it as a mechanism for accelerating the delivery of high-quality care. Developers who focused on proactive documentation and utilized specialized review organizations found themselves better equipped to navigate international market entry. In the long term, these strategies allowed advanced medical software to remain cutting-edge while adhering to the most rigorous standards, thereby providing clear pathways for future innovation in patient technology.
